BrainsWay Ltd. (NASDAQ:BWAY – Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 27,200 shares, a decline of 44.7% from the August 31st total of 49,200 shares. Based on an average daily volume of 73,800 shares, the short-interest ratio is presently 0.4 days.
BrainsWay Price Performance
Shares of NASDAQ:BWAY traded up $0.01 during midday trading on Thursday, hitting $8.27. The company had a trading volume of 30,960 shares, compared to its average volume of 92,959. The company has a market cap of $137.94 million, a price-to-earnings ratio of -91.77 and a beta of 1.25. BrainsWay has a 12-month low of $3.09 and a 12-month high of $8.75. The company has a fifty day moving average of $7.56 and a two-hundred day moving average of $6.40.
BrainsWay (NASDAQ:BWAY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $9.40 million. During the same period in the prior year, the business posted ($0.05) EPS. Research analysts expect that BrainsWay will post 0.06 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BrainsWay
Analyst Upgrades and Downgrades
Several research firms recently issued reports on BWAY. Northland Securities upped their price objective on BrainsWay from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of BrainsWay in a report on Monday, September 16th.
View Our Latest Research Report on BWAY
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Articles
- Five stocks we like better than BrainsWay
- Stock Market Sectors: What Are They and How Many Are There?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Do ETFs Pay Dividends? What You Need to Know
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Pros And Cons Of Monthly Dividend Stocks
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.